MedTrace Logo

Optimizing HBV Management During Anti-CD20 Antibodies

NCT03155984 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2018-05-04

No results posted yet for this study

Summary

Hepatitis B virus (HBV) reactivation is common during anti-CD20 containing chemotherapy, even in HBsAg-negative patients with only prior HBV exposure. The optimal timing of commencing antiviral therapy and the interval of clinical monitoring is uncertain. 25% of the Hong Kong population has prior HBV exposure. The investigators plan monitor this cohort of patients and determine (1) the optimal time point for starting antiviral therapy based on the progression of HBV reactivation, and (2) the optimal interval of clinical monitoring.

Conditions

Interventions

DRUG

Anti-CD20 antibody

All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-01
Primary Completion
2017-06-01
Completion
2017-12-01
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03155984 on ClinicalTrials.gov